FRONTIER 2: Efficacy and Safety of JNJ-77242113 in Moderate to Severe Plaque Psoriasis
Research type
Research Study
Full title
A Phase 2b Multicenter, Long-Term Extension, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis.
IRAS ID
1005014
Contact name
David Wright
Contact email
Sponsor organisation
Janssen-Cilag International NV
Eudract number
2021-004320-16
ISRCTN Number
ISRCTN15135908
Clinicaltrials.gov Identifier
Research summary
Plaque psoriasis is a common, chronic, inflammatory condition, affecting about 3.5 million patients in the United States, European Union and Japan. Despite advanced treatment options, large numbers of patients are not receiving these therapies. There is a need for safer options, fewer injections, and more effective oral medications. Janssen has an investigational drug called JNJ-77242113, which targets immune responses in body and skin that impact diseases, such as psoriasis.
It is hoped that targeting immune response processes may lead to less inflammation and reduction in psoriasis disease activity.
This study is a follow-on trial of 77242113PSO2001, which is designed to evaluate long-term efficacy and safety of the investigational drug JNJ-77242113 in adults with moderate to severe plaque psoriasis.REC name
South Central - Berkshire B Research Ethics Committee
REC reference
22/SC/0224
Date of REC Opinion
3 Aug 2022
REC opinion
Further Information Favourable Opinion